Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Subscribe To Our Newsletter & Stay Updated
